Gufic Biosciences has received patents from the Intellectual Property India, The Patent Office, Government of India, for two formulations - parental formulation of anidulafungin and a freeze dried parental composition of tigecycline.
Anidulafungin is a semisynthetic echinocandin used as an antifungal drug. On the other hand, tigecycline, a glycylcycline that is administered intravenously, is an antibiotic used to treat a number of bacterial infections.
The company said that it was in the process of applying patents for the two formulations in other countries as well.
Gufic Group manufactures pharmaceutical and herbal products along with a wide range of APIs. It is one of the leading manufacturers of lyophilised injections in India and makes lyophilised products such as antibiotic, antifungal, cardiac, infertility, antiviral and proton-pump inhibitor segments.
Gufic group has three facilities in India - at Navsari & Vadodara in Gujarat and Belgaum in Karnataka - and one production plant in Uzbekistan. Navsari is the group’s lyophilised formulation, API and herbal manufacturing facility. While Vadodara plant manufactures personal hygiene product, its herbal formulation manufacturing facility is located at Belgaum.
